Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation
This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.
Oncology CME
Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer
This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.
Early Palliative Care Intervention Improves Satisfaction with Care, Prevents Decline in QOL in Patients with Metastatic Disease
This CME activity from ASCO 2012 describes the benefits of early palliative care in patients with metastatic cancer.
Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma
This CME activity from ASCO 2012 reviews carfilzomib, lenalidomide, and low-dose dexamethasone in patients with newly diagnosed multiple myeloma.
Pomalidomide Active in Patients with Multiple Myeloma Refractory to Lenalidomide, Bortezomib—or Both—and in Transplant Failures
This CME activity reviews pomalidomide in combination with low-dose dexamethasone in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both.
Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer
This CME activity from ASCO 2012 reviews abiraterone acetate plus prednisone in patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer.
Continuous—vs Intermittent—Androgen Deprivation Extends Overall Survival in Men with Minimal Disease Hormone-Sensitive Metastatic Prostate Cancer
This CME activity from ASCO 2012 reviews continuous androgen deprivation for hormone-sensitive metastatic prostate cancer in men with minimal disease spread.
Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-Free Survival in Patients with High-Risk, Node-Negative Breast Cancer
A phase 3 trial presented at ASCO showed FAC plus weekly paclitaxel was associated with a slight but clinically relevant improvement in DFS vs FAC alone.
First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+ Metastatic Breast Cancer
Taxane-based chemotherapy combined with lapatinib results in shorter PFS than with trastuzumab in patients with HER2+ metastatic breast cancer.
T-DM1 Found to Prolong Progression-Free Survival in Patients with HER2+ Metastatic Breast Cancer
Patients with HER2+ locally advanced or metastatic breast cancer experience improved survival with T-DM1.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...